A Double-Blind, Placebo-Controlled, Parallel Design Phase 3 Study to Assess the Efficacy, Safety, Tolerability, and Pattern of Use of SM-1 in Adult Subjects With a History of Transient Insomnia
Overview
- Phase
- Phase 3
- Intervention
- SM-1
- Conditions
- Transient Insomnia
- Sponsor
- Sequential Medicine Ltd
- Primary Endpoint
- Subjective Total Sleep Time
- Status
- Withdrawn
- Last Updated
- 2 years ago
Overview
Brief Summary
The purpose of this study is to assess the efficacy and pattern of use of the combination drug product SM-1 in adults who sometimes have difficulty in falling asleep or staying asleep, but who do not have chronic insomnia. Participants will receive SM-1 or placebo to take at home as needed over the course of 3 months treatment period.
Detailed Description
The purpose of this study is to assess the efficacy, safety, tolerability and pattern of use of SM-1 in adults who sometimes have difficulty in falling asleep or staying asleep, but who do not have chronic insomnia. SM-1 is a combination drug product containing diphenhydramine, zolpidem and lorazepam. The study is a parallel group design; participants will receive either SM-1 or placebo to take at home as needed over the course of 3 months treatment period.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Experienced at least 1 prior episode of transient insomnia meeting all of the following criteria: difficulty falling asleep or staying asleep; next day impairment or distress associated with the disturbed sleep; frequency of 1 to 7 nights per week; duration of less than 1 month or more than 1 month of intermittent episodes.
- •Routinely spends 6.5 - 9.5 hours in bed each night, with bed time varying no more than 2 hours over a week.
- •Body Mass Index (BMI) between 19 and 32 kg/m
- •Good general health, as determined by a thorough medical, sleep and psychiatric history review, brief physical examination including vital sign measurements, and an assessment of screening laboratory test results.
- •Agrees, for the duration of the study, to take only study drug to address difficulty falling asleep or staying asleep, and to not drink alcohol within 2 hours of expected bedtime.
Exclusion Criteria
- •Females who are pregnant, breast-feeding, or planning a pregnancy during the study period.
- •Clinically significant medical disorder or currently unstable medical condition that, in the opinion of the investigator, would confound the results of the study.
- •Abnormal laboratory value at screening, judged clinically significant by the investigator.
- •History or current evidence of severe hepatic (liver) impairment.
- •Clinically significant psychiatric illness, or the history or presence of a major psychiatric illness in the past year.
- •Has a significant risk (in the opinion of the investigator) for suicidal behavior during the course of participation in the study or a) At screening: the subject scores "yes" on items 4 or 5 in the Suicidal Ideation section of the C-SSRS with reference to a 6-month period prior to screening; or b) At screening: the subject has had one or more suicidal attempts within a 2-year period prior to screening; or c) At the baseline visit: the subject scores "yes" on items 4 or 5 in the Suicidal Ideation section of the C-SSRS with reference to screening; or d) The subject is considered to be an imminent danger to self or others.
- •Has a history of chronic insomnia or other sleep disorders, such as sleep apnea, narcolepsy, parasomnia, restless leg syndrome, or circadian rhythm disorder.
- •Has used medications to aid sleep on most nights during the past 2 months.
- •Has a history of night work or shift work within the month prior to screening or a need to participate in night work or shift work during the study.
- •Has a history of alcohol or substance use disorder within the year prior to screening, or current evidence of alcohol or substance use disorder as defined by the Diagnostic and Statistical Manual of the American Psychiatric Association, 5th Edition.
Arms & Interventions
Experimental (SM-1)
Drug: SM-1 3-drug combination product containing 50-mg diphenhydramine, 5-mg delayed-release zolpidem and 0.5-mg delayed-release lorazepam.
Intervention: SM-1
Placebo
Drug: Placebo Identical in appearance to SM-1 and has the same excipients, but no active ingredients or delayed-release coating materials.
Intervention: Placebo
Outcomes
Primary Outcomes
Subjective Total Sleep Time
Time Frame: 7 nights
Total time spent sleeping each night as reported by the subject
Secondary Outcomes
- Safety Residual Effects(Through study completion, 17 weeks)
- Safety Adverse Events(Through study completion, 17 weeks)
- Pattern of use(3 months)
- Safety Rebound Insomnia(Through study completion, 17 weeks)